Autologous Osteoperiosteal Transplantation for the Treatment of Severe Osteochondral Lesions of the Talus
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-60
SponsorPeking University Third Hospital
About this trial
The goal of this clinical trial is to establish a multicenter prospective cohort of patients with severe osteochondral lesion of the talus (OLT), evaluate the clinical efficacy of autologous osteoperiosteal transplantation and the incidence of postoperative donor-site morbidity. The main questions it aims to answer are:
Does autologous osteoperiosteal transplantation have good clinical outcomes in the treatment of severe OLT? Does autologous osteoperiosteal transplantation treat severe OLT with fewer postoperative complications?
Participants will:
Undergo autologous osteoperiosteal transplantation for OLT Receive clinical follow-up 3, 6, 12, and 24 months after surgery and answer scales of ankle function assessment Take CT and MRI preoperatively and 12 and 24 months after surgery
Eligibility criteria
Qualifiers
Chronic ankle pain, diagnosed as Osteochondral Lesions of the Talus (OLT);
Hepple V OLT on the medial side of the talus or the diameter of the lesion ≥ 8 mm;
Conservative treatment of at least 3 months fails to relieve symptoms;
Willingness to voluntarily participate in the trial and to sign informed consent.
Disqualifiers
Varus or valgus deformity of the ankle of more than 5 degrees;
Grade III injury of the lateral collateral ligament of ankle;
Chronic synovitis (rheumatoid arthritis, pigmented villous nodular synovitis, etc.);
Joint fibrosis, stiffness, and significantly restricted range of motion;
Trial design
Treatments tested in this trial
- Autologous Osteoperiosteal Transplantation
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov